- Home
- AIHS vs SILO Comparison
AIHS vs SILO Comparison
Compare AIHS & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIHS
- SILO
- Stock Information
- Founded
- AIHS 2014
- SILO 2010
- Country
- AIHS China
- SILO United States
- Employees
- AIHS N/A
- SILO N/A
- Industry
- AIHS Finance: Consumer Services
- SILO Apparel
- Sector
- AIHS Finance
- SILO Consumer Discretionary
- Exchange
- AIHS Nasdaq
- SILO Nasdaq
- Market Cap
- AIHS 9.5M
- SILO 8.8M
- IPO Year
- AIHS 2018
- SILO N/A
- Fundamental
- Price
- AIHS $0.88
- SILO $1.35
- Analyst Decision
- AIHS
- SILO
- Analyst Count
- AIHS 0
- SILO 0
- Target Price
- AIHS N/A
- SILO N/A
- AVG Volume (30 Days)
- AIHS 13.9K
- SILO 228.4K
- Earning Date
- AIHS 02-14-2025
- SILO 03-04-2025
- Dividend Yield
- AIHS N/A
- SILO N/A
- EPS Growth
- AIHS N/A
- SILO N/A
- EPS
- AIHS N/A
- SILO N/A
- Revenue
- AIHS $5,878,700.00
- SILO $72,102.00
- Revenue This Year
- AIHS N/A
- SILO $1.86
- Revenue Next Year
- AIHS N/A
- SILO N/A
- P/E Ratio
- AIHS N/A
- SILO N/A
- Revenue Growth
- AIHS 12.21
- SILO N/A
- 52 Week Low
- AIHS $0.70
- SILO $0.77
- 52 Week High
- AIHS $1.45
- SILO $4.50
- Technical
- Relative Strength Index (RSI)
- AIHS 46.48
- SILO 40.14
- Support Level
- AIHS $0.87
- SILO $1.39
- Resistance Level
- AIHS $1.03
- SILO $1.52
- Average True Range (ATR)
- AIHS 0.07
- SILO 0.14
- MACD
- AIHS -0.00
- SILO -0.05
- Stochastic Oscillator
- AIHS 6.06
- SILO 0.97
About AIHS Senmiao Technology Limited
Senmiao Technology Ltd is a holding company. The company's operating segment includes Automobile Transaction and Related Services focusing on the online ride-hailing industry in the People's Republic of China and Online ride-hailing platform Services through its own platform, Xixingtianxia. It generates maximum revenue from the Automobile Transaction and Related Services segment. Geographically, it derives revenue from China.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.